Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10444)
All Articles published online
|
Publishing Process of This Article
|
Feb 21, 2016 (publication date) through Feb 15, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Liu Y, Gao LF, Liang XH, Ma CH. Role of Tim-3 in hepatitis B virus infection: An overview. World J Gastroenterol 2016; 22(7): 2294-2303 [PMID: 26900291 DOI: 10.3748/wjg.v22.i7.2294] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i7/2294.htm |
| Number | Citing Articles |
| 1 |
Bing-Yi Zhang, Dan-Ping Chai, Yi-Hang Wu, Li-Peng Qiu, Yong-Yong Zhang, Zi-Hong Ye, Xiao-Ping Yu. Potential Drug Targets Against Hepatitis B Virus Based on Both Virus and Host Factors. Current Drug Targets 2019; 20(16): 1636 doi: 10.2174/1389450120666190729115646
|
| 2 |
Mazdak Ganjalikhani Hakemi, Morteza Jafarinia, Mahdieh Azizi, Mahsa Rezaeepoor, Orkhan Isayev, Alexandr V. Bazhin. The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.601661
|
| 3 |
Shanshan Wu, Xinfang Du, Guohua Lou, Shuihong Yu, Kecong Lai, Jinjin Qi, Shujun Ni, Zhi Chen, Feng Chen. Expression changes of Tim-3 as one of supplementary indicators for monitoring prognosis of liver pathological changes in chronic HBV infection. BMC Infectious Diseases 2022; 22(1) doi: 10.1186/s12879-022-07841-1
|
| 4 |
Jonathan Charles, Andrea Vrionis, Arian Mansur, Trevor Mathias, Jamil Shaikh, Aaron Ciner, Yixing Jiang, Nariman Nezami. Potential Immunotherapy Targets for Liver-Directed Therapies, and the Current Scope of Immunotherapeutics for Liver-Related Malignancies. Cancers 2023; 15(9): 2624 doi: 10.3390/cancers15092624
|
| 5 |
Antonio Riva, Shilpa Chokshi. Immune checkpoint receptors: homeostatic regulators of immunity. Hepatology International 2018; 12(3): 223 doi: 10.1007/s12072-018-9867-9
|
| 6 |
Xinyan Xue, Jing Wang, Ke Fu, Shu Dai, Rui Wu, Cheng Peng, Yunxia Li. The role of miR-155 on liver diseases by modulating immunity, inflammation and tumorigenesis. International Immunopharmacology 2023; 116: 109775 doi: 10.1016/j.intimp.2023.109775
|
| 7 |
João Panão Costa, Armando de Carvalho, Artur Paiva, Olga Borges. Insights into Immune Exhaustion in Chronic Hepatitis B: A Review of Checkpoint Receptor Expression. Pharmaceuticals 2024; 17(7): 964 doi: 10.3390/ph17070964
|
| 8 |
Victoria C. Brom, Christof Burger, Dieter C. Wirtz, Frank A. Schildberg. The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.837645
|
| 9 |
Mehul Patel, Aashka Thakkar, Priya Bhatt, Umang Shah, Ashish Patel, Nilay Solanki, Swayamprakash Patel, Sandip Patel, Karan Gandhi, Bhavesh Patel. Prominent Targets for Cancer Care: Immunotherapy Perspective. Current Cancer Therapy Reviews 2023; 19(4): 298 doi: 10.2174/1573394719666230306121408
|
| 10 |
Prachie Sharma, Kamal Rawal, Kapila Kumar. Assesment Of Different Aspects Of Hepatitis B Viral Lymphotropism Using Deep Curation. F1000Research 2022; 11: 984 doi: 10.12688/f1000research.109779.1
|
| 11 |
Xin Meng, Guofang Xia, Lili Zhang, Congfeng Xu, Zhong Chen. T cell immunoglobulin and mucin domain-containing protein 3 is highly expressed in patients with acute decompensated heart failure and predicts mid-term prognosis. Frontiers in Cardiovascular Medicine 2022; 9 doi: 10.3389/fcvm.2022.933532
|
| 12 |
Jia-Rui Zheng, Zi-Long Wang, Bo Feng. Hepatitis B functional cure and immune response. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.1075916
|
| 13 |
Zhu Li, Na Li, Fang Li, Zhihua Zhou, Jiao Sang, Yanping Chen, Qunying Han, Yi Lv, Zhengwen Liu. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. Medicine 2016; 95(52): e5749 doi: 10.1097/MD.0000000000005749
|
| 14 |
Robério Amorim de Almeida Pondé, Guilherme de Sousa Pondé Amorim. Elimination of the hepatitis B virus: A goal, a challenge. Medicinal Research Reviews 2024; 44(5): 2015 doi: 10.1002/med.22030
|
| 15 |
Jil M. Jubel, Zachary R. Barbati, Christof Burger, Dieter C. Wirtz, Frank A. Schildberg. The Role of PD-1 in Acute and Chronic Infection. Frontiers in Immunology 2020; 11 doi: 10.3389/fimmu.2020.00487
|
| 16 |
Huimin Dong, Yuan Liao, Mei Shang, Yuechun Fu, Hongbin Zhang, Minqi Luo, Bo Hu. Effects of co-infection with Clonorchis sinensis on T cell exhaustion levels in patients with chronic hepatitis B. Journal of Helminthology 2024; 98 doi: 10.1017/S0022149X23000871
|
| 17 |
Hridesh Banerjee, Lawrence P. Kane. Immune regulation by Tim-3. F1000Research 2018; 7: 316 doi: 10.12688/f1000research.13446.1
|
| 18 |
Jiaoli Zhang, Zhenni Wang, Wei Yang, Jungang Zhang, Yong Wang, Jinlin Liu. Re: “CXCR5+ CD8+ T Cells Indirectly Offer B Cell Help and Are Inversely Correlated with Viral Load in Chronic Hepatitis B Infection” by Jiang et al. (DNA Cell Biol 2017;36, 321–327). DNA and Cell Biology 2019; 38(1): 107 doi: 10.1089/dna.2018.4278
|
| 19 |
Julie Joseph, Benjamin Rahmani, Yonesha Cole, Neha Puttagunta, Edward Lin, Zafar K. Khan, Pooja Jain. Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?. Journal of Neuroimmune Pharmacology 2022; 17(3-4): 381 doi: 10.1007/s11481-021-10018-3
|
| 20 |
Reza Karami, Mehrdad Fathi, Pooya Jalali, Hadi Hassannia, Asieh Zarei, Mohammad Hojjat-Farsangi, Farhad Jadidi. The emerging role of TIM-3 in colorectal cancer: a promising target for immunotherapy. Expert Opinion on Therapeutic Targets 2024; 28(12): 1093 doi: 10.1080/14728222.2024.2442437
|
| 21 |
Junyan Wang, Chan Li, Juanjuan Fu, Xia Wang, Xia Feng, Xiucheng Pan. Tim‐3 regulates inflammatory cytokine expression and Th17 cell response induced by monocytes from patients with chronic hepatitis B. Scandinavian Journal of Immunology 2019; 89(5) doi: 10.1111/sji.12755
|
| 22 |
Ailyn Fadriquela, Cheol-Su Kim, Kyu-Jae Lee, Seong Hee Kang, Moon Young Kim, Jong-Han Lee. Soluble type immune checkpoint regulators using multiplex luminex immunoassay in chronic hepatitis B patients. Journal of Clinical Pathology 2021; 74(12): 780 doi: 10.1136/jclinpath-2020-207125
|
| 23 |
Natalia Sauer, Natalia Janicka, Wojciech Szlasa, Bartłomiej Skinderowicz, Katarzyna Kołodzińska, Wioletta Dwernicka, Małgorzata Oślizło, Julita Kulbacka, Vitalij Novickij, Katarzyna Karłowicz-Bodalska. TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. Cancer Immunology, Immunotherapy 2023; 72(11): 3405 doi: 10.1007/s00262-023-03516-1
|
| 24 |
Krupa R. Mysore, Rafik M. Ghobrial, Sunil Kannanganat, Laurie J. Minze, Edward A. Graviss, Duc T. Nguyen, Katherine K. Perez, Xian C. Li. Longitudinal assessment of T cell inhibitory receptors in liver transplant recipients and their association with posttransplant infections. American Journal of Transplantation 2018; 18(2): 351 doi: 10.1111/ajt.14546
|
| 25 |
Yamei Li, Yangjuan Bai, Hua Zhang, Yi Li, Lin Yan, Xueqiao Wang, Jiwen Fan, Yunfei An, Zhengli Wan, Shumeng Hu, Lanlan Wang, Yunying Shi. Decreased expression of ADAM10 on monocytes is associated with chronic allograft dysfunction in kidney transplant recipients. International Immunopharmacology 2023; 115: 109710 doi: 10.1016/j.intimp.2023.109710
|
| 26 |
Elia Moreno-Cubero, Juan-Ramón Larrubia. Specific CD8<sup>+</sup> T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. World Journal of Gastroenterology 2016; 22(28): 6469-6483 doi: 10.3748/wjg.v22.i28.6469
|
| 27 |
Soheil Tavakolpour, Seyed Moayed Alavian, Shahnaz Sali. Manipulation of Regulatory Cells’ Responses to Treatments for Chronic Hepatitis B Virus Infection. Hepatitis Monthly 2016; 16(6) doi: 10.5812/hepatmon.37927
|
| 28 |
Salvatore Chirumbolo. Baicalin in flavocoxid may act against hepatitis B virus via a pro-inflammatory pathway. Inflammation Research 2018; 67(3): 203 doi: 10.1007/s00011-017-1111-x
|
| 29 |
Xianhong Du, Zhuanchang Wu, Yong Xu, Yuan Liu, Wen Liu, Tixiao Wang, Chunyang Li, Cuijuan Zhang, Fan Yi, Lifen Gao, Xiaohong Liang, Chunhong Ma. Increased Tim-3 expression alleviates liver injury by regulating macrophage activation in MCD-induced NASH mice. Cellular & Molecular Immunology 2019; 16(11): 878 doi: 10.1038/s41423-018-0032-0
|
| 30 |
Bo Zhang, Tianyu Miao, Xin Shen, Lirong Bao, Cheng Zhang, Caixia Yan, Wei Wei, Jiao Chen, Liying Xiao, Chongkui Sun, Jintao Du, Yan Li. EB virus-induced ATR activation accelerates nasopharyngeal carcinoma growth via M2-type macrophages polarization. Cell Death & Disease 2020; 11(9) doi: 10.1038/s41419-020-02925-9
|
| 31 |
Christian Bailly, Xavier Thuru, Laurence Goossens, Jean-François Goossens. Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases. Biochemical Pharmacology 2023; 209: 115445 doi: 10.1016/j.bcp.2023.115445
|
| 32 |
Ping Zhang, Yan Wang, Xue‑Rong Liu, Shi‑Ru Hong, Jian Yao. Downregulated Tim‑3 expression is responsible for the incidence and development of colorectal cancer. Oncology Letters 2018; doi: 10.3892/ol.2018.8697
|
| 33 |
Yamei Li, Yangjuan Bai, Huang Zhang, Yi Li, Lin Yan, Xueqiao Wang, Jiwen Fan, Yunfei An, Zhengli Wan, Shumeng Hu, Lanlan Wang, Yun Ying Shi. Decreased Expression of ADAM10 on Monocytes is Associated with Chronic Allograft Dysfunction in Kidney Transplant Recipients. SSRN Electronic Journal 2022; doi: 10.2139/ssrn.4197799
|
| 34 |
Lucile Dumolard, Caroline Aspord, Patrice N. Marche, Zuzana Macek Jilkova. Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1148111
|